Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form 4

ACHILLION Form 4 January 19, 2	N PHARMACEU	TICALS	INC						
Check th if no long subject to Section 1 Form 4 o Form 5 obligation may cont See Instru 1(b).	14 UNITED is box ger 6. or ns cinue. uction	MENT OF rsuant to S (a) of the I	Wa F CHAN Section Public U	nshington NGES IN SECUF 16(a) of th	, D.C. 20 BENEF RITIES le Securi ding Cor	9549 ICIAL O ties Excha npany Ac	E COMMISSION WNERSHIP OF ange Act of 1934, t of 1935 or Sectio 1940	OMB Number: Expires: Estimated burden hou response	urs per
1. Name and Address of Reporting Person <u>*</u> Verwiel Frank			2. Issuer Name and Ticker or Trading Symbol ACHILLION PHARMACEUTICALS INC [ACHN]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_ Director 10% Owner			
(Last) C/O ACHIL PHARMAC GEORGE S	LION EUTICALS, IN	Middle) C., 300		of Earliest T Day/Year) 2017	ransaction		Officer (give below)	titleOth below)	er (specify
(Street) NEW HAVEN, CT 06511			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities .	Acquired, Disposed o	f, or Beneficia	lly Owned
	2. Transaction Date (Month/Day/Year)	2A. Deemo Execution any (Month/Da	ed Date, if	3. Transactio Code (Instr. 8) Code V	4. Securit nAcquired Disposed (Instr. 3, -	ies (A) or of (D)	5. Amount of Securities H Beneficially (Owned (Following (Reported Transaction(s) (Instr. 3 and 4)	5. Ownership Form: Direct D) or Indirect I) Instr. 4)	7. Nature of Indirect
Reminder: Rep	oort on a separate line	e for each cla	ass of sec	urities bene	Perso inforr requi	ons who re nation con red to resp	or indirectly. spond to the collect tained in this form bond unless the for ently valid OMB cor	are not m	SEC 1474 (9-02)

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option	\$ 4.09	01/19/2017		А	30,000	<u>(1)</u>	01/19/2027	Common Stock	30,000

Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form 4

Reporting Owners

Reporting Owner Name / Address		Relationships					
		Director	10% Owner	Officer	Other		
Verwiel Frank C/O ACHILLION PHARMACEUTICALS 300 GEORGE STREET NEW HAVEN, CT 06511	S, INC.	Х					
Signatures							
/s/ Mary Kay Fenton, attorney-in-fact	01/19/201	7					

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option vests as to 25% of the original number of shares on the date of grant and as to an additional 2.08% of the original number of shares at the end of each monthly period thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.